Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. November 2018 08:00 ET | Quelle: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder

CHARLOTTESVILLE, Va., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
14. November 2018 08:00 ET | Quelle: Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Provides Business Update for the Third Quarter of 2018

CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
08. November 2018 09:20 ET | Quelle: Adial Pharmaceutical, Inc.

Addiction Drug Developer Adial Pharmaceuticals Receives Notice of Allowance of Canadian Patent for AD04 in Alcohol Use Disorder

CHARLOTTESVILLE, Va., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
23. Oktober 2018 08:00 ET | Quelle: Adial Pharmaceutical, Inc.

Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

CHARLOTTESVILLE, Va., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
18. September 2018 07:30 ET | Quelle: Adial Pharmaceutical, Inc.

Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent

Patent portfolio significantly enhanced and extended by this patent CHARLOTTESVILLE, Va., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage...
12. September 2018 09:00 ET | Quelle: Adial Pharmaceutical, Inc.

Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results

Genetically targeted AD04 drug candidate indicates stability at four-year point as it moves toward Phase 3 clinical trial CHARLOTTESVILLE, Va., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Adial...
04. September 2018 08:00 ET | Quelle: Adial Pharmaceutical, Inc.

Adial Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell this Morning at 9:30 AM Eastern

CHARLOTTESVILLE, Va., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
27. August 2018 09:00 ET | Quelle: Adial Pharmaceutical, Inc.

Leading Addiction Focused Company Adial Pharmaceuticals Comments on Lancet Article Reporting Alcohol is the Number One Cause of Death Globally Among Ages 15 to 49

Adial seeks to rapidly advance its drug AD04 through Phase 3 trialsto become an important tool in combating alcohol use disorder CHARLOTTESVILLE, Va., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Adial...
15. August 2018 08:00 ET | Quelle: Adial Pharmaceutical, Inc.

Adial Pharmaceuticals Announces Appointment of Monika Rogozinska as Senior Vice President of Drug and Business Development

CHARLOTTESVILLE, Va., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent...
31. Juli 2018 16:05 ET | Quelle: Adial Pharmaceutical, Inc.

Adial Pharmaceuticals Announces Closing of Initial Public Offering

CHARLOTTESVILLE, Va., July 31, 2018 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of a...

Vorherige Seite

Nächste Seite